| # | Drug | Count |
|---|---|---|
| 0 | CYCLOPHOSPHAMIDE | 54 |
| 1 | CYCLOPHOSPHAMIDE FOR INJECTION | 54 |
| 2 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 54 |
| 3 | CARBOPLATIN | 45 |
| 4 | LETROZOLE | 44 |
| 5 | DOXORUBICIN | 43 |
| 6 | GEMCITABINE HYDROCHLORIDE | 40 |
| 7 | CYTARABINE | 37 |
| 8 | RIBOCICLIB | 37 |
| 9 | DEXAMETHASONE | 36 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | BEVACIZUMAB-MALY | 1 | 0.0050 |
| 1 | TRASTUZUMAB-ANNS | 5 | 0.0033 |
| 2 | RADIUM RA 223 DICHLORIDE | 16 | 0.0032 |
| 3 | CARMUSTINE | 11 | 0.0023 |
| 4 | TOREMIFENE CITRATE | 1 | 0.0023 |
| 5 | TOPOTECAN | 13 | 0.0021 |
| 6 | GLASDEGIB | 1 | 0.0021 |
| 7 | FLUTAMIDE | 2 | 0.0020 |
| 8 | FILGRASTIM-AAFI | 1 | 0.0015 |
| 9 | VINORELBINE | 9 | 0.0013 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 84 |
| 1 | Alkylating Drug [EPC] | 77 |
| 2 | Nucleoside Metabolic Inhibitor [EPC] | 72 |
| 3 | Platinum-based Drug [EPC] | 72 |
| 4 | Aromatase Inhibitor [EPC] | 64 |
| 5 | Kinase Inhibitor [EPC] | 43 |
| 6 | Microtubule Inhibitor [EPC] | 41 |
| 7 | Topoisomerase Inhibitor [EPC] | 38 |
| 8 | Estrogen Receptor Antagonist [EPC] | 36 |
| 9 | Nonsteroidal Anti-inflammatory Drug [EPC] | 34 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Peroxisome Proliferator-activated Receptor Agonist [EPC] | 1 | 0.0011 |
| 1 | Adrenal Steroid Synthesis Inhibitor [EPC] | 1 | 0.0010 |
| 2 | Estrogen Receptor Antagonist [EPC] | 36 | 0.0009 |
| 3 | Radioligand Therapeutic Agent [EPC] | 8 | 0.0006 |
| 4 | Aromatase Inhibitor [EPC] | 64 | 0.0006 |
| 5 | Bispecific CD20-directed CD3 T Cell Engager [EPC] | 2 | 0.0005 |
| 6 | Topoisomerase Inhibitor [EPC] | 38 | 0.0005 |
| 7 | Actinomycin [EPC] | 1 | 0.0005 |
| 8 | Oxazolidinone Antibacterial [EPC] | 10 | 0.0003 |
| 9 | Alkylating Drug [EPC] | 77 | 0.0003 |